In the early days of the coronavirus pandemic, many drugmakers saw major share price declines as investors got to grips with the likely impact on prescribing, developing medicines, and supply chain interruptions.
The second half of 2020 pointed to a more positive outlook, with stocks recovering, but economic and supply chain volatility have continued to hamper the sector, as well as the broader economy.
To help respond to changing market conditions and improve output, companies could try what is known as a postponement strategy in supply chain management.
Amid growing pressure to meet a backlog of demand for healthcare treatment, this could help companies prevent shortages and head off delays to clinical research.
With us today to help make clear the benefits of a postponement strategy, and to outline key business considerations in implementing the approach, are Lee Feander and Jan Diederichsen of professional services firm Alvarez & Marsal.